Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: Original data and review of the literature

Journal of Molecular Neuroscience

Volumn 23, Issue 1-2, 2004, Pages 115-122

  Lewczuk, Piotr ^a   Esselmann, Hermann ^b   Bibl, Mirko ^b   Beck, Georg ^a   Maler, Juan Manuel ^a   Otto, Markus ^b   Kornhuber, Johannes ^a   Wiltfang, Jens ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Alzheimer's dementia; Cerebrospinal fluid; Neurofibrillary tangles; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN; THREONINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MEMORY DISORDER; NEUROCHEMISTRY; PATHOGENESIS; PATIENT; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; AGE; AMINO ACID SEQUENCE; BRAIN; CHEMISTRY; METABOLISM; MIDDLE AGED; NEUROFIBRILLARY TANGLE; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PREDICTION AND FORECASTING; REPRODUCIBILITY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; BRAIN; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROFIBRILLARY TANGLES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TAU PROTEINS; THREONINE;

EID: 4344626089     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:23:1-2:115     Document Type: Article

References (44)

1. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., and Blennow K. (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58, 373-379.
2. Arai H., Ishiguro K., Ohno H., Moriyama M., Itoh N., Okamura N., et al. (2000) CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp. Neurol. 166, 201-203.
3. Arriagada P. V., Growdon J. H., Hedley-Whyte E. T., and Hyman B. T. (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
4. Augustinack J. C., Schneider A., Mandelkow E. M., and Hyman B. T. (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. (Berl.) 103, 26-35.
5. Baas P. W., Pienkowski T. P., and Kosik K. S. (1991) Processes induced by tau expression in Sf9 cells have an axon-like microtubule organization. J. Cell Biol. 115, 1333-1344.
6. Blennow K., Vanmechelen E., and Hampel H. (2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol. Neurobiol. 24, 87-97.
7. Braak H. and Braak E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82, 239-259.
8. Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., and Hof P. R. (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33, 95-130.
9. Buerger K., Zinkowski R., Teipel S. J., Tapiola T., Arai H., Blennow K., et al. (2002) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol. 59, 1267-1272.
10. Consensus Report (1998) Consensus Report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol. Aging 19, 109-116.
11. Dawson H. N., Ferreira A., Eyster M. V., Ghoshal N., Binder L. I., and Vitek M. P. (2001) Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell Sci. 114, 1179-1187.
12. Drewes G., Trinczek B., Illenberger S., Biernat J., Schmitt-Ulms G., Meyer H. E., et al. (1995) Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262. J. Biol. Chem. 270, 7679-7688.
13. Folstein M. F., Folstein S. E., and McHugh P. R. (1975) "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198.
14. Galasko D., Chang L., Motter R., Clark C. M., Kaye J., Knopman D., et al. (1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 55, 937-945.
15. Grundke-Iqbal I., Iqbal K., Tung Y. C., Quinlan M., Wisniewski H. M., and Binder L. I. (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA 83, 4913-4917.
16. Hampel H., Buerger K., Kohnken R., Teipel S. J., Zinkowski R., Moeller H. J., et al. (2001) Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann. Neurol. 49, 545-546.
17. Hampel H., Buerger K., Zinkowski R., Teipel S. J., Goernitz A., Andreasen J., et al. (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry. 61, 95-102.
18. Harada A., Oguchi K., Okabe S., Kuno J., Terada S., Ohshima T., et al. (1994) Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369, 488-491.
19. Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E., and Blennow K. (2001) Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett. 297, 187-190.
20. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H. C., Riemenschneider M., De Deyn P. P., et al. (1999) Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology 52, 1555-1562.
21. Iqbal K., Alonso Adel C., El-Akkad E., Gong C. X., Haque N., Khatoon S., et al. (2002) Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. J. Mol. Neurosci. 19, 95-99.
22. Itoh N., Arai H., Urakami K., Ishiguro K., Ohno H., Hampel H., et al. (2001) Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann. Neurol. 50, 150-156.
23. Knops J., Kosik K. S., Lee G., Pardee J. D., Cohen-Gould L., and McConlogue L. (1991) Overexpression of tau in a nonneuronal cell induces long cellular processes. J. Cell Biol. 114, 725-733.
24. Kohnken R., Buerger K., Zinkowski R., Miller C., Kerkman D., DeBernardis J., et al. (2000) Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 287, 187-190.
25. Lewczuk P., Esselmann H., Meyer M., Wollscheid V., Neumann M., Otto M., et al. (2003) The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid (CSF) in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun. Mass Spectrom. 17, 129-196.
26. Maurer K., Volk S., and Gerbaldo H. (1997) Auguste D and Alzheimer's disease. Lancet 349, 1546-1549.
27. Mawal-Dewan M., Henley J., Van de Voorde A., Trojanowski J. Q., and Lee V. M. (1994) The phosphorylation state of tau in the developing rat brain is regulated by phosphoprotein phosphatases. J. Biol. Chem. 269, 30981-30987.
28. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
29. Nagga K., Gottfries J., Blennow K., and Marcusson J. (2002) Cerebrospinal fluid phospho-Tau, total Tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Dement Geriatr. Cogn. Disord. 14, 183-190.
30. Otto M., Wiltfang J., Tumani H., Zerr I., Lantsch M., Kornhuber J., et al. (1997) Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 225, 210-212.
31. Papassotiropoulos A., Streffer J. R., Tsolaki M., Schmid S., Thal D., Nicosia F., et al. (2003) Increased brain beta-amyloid load, phosphorylated Tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch. Neurol. 60, 29-35.
32. Parnetti L., Lanari A., Amici S., Gallai V., Vanmechelen E., and Hulstaert F. (2001) CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol. Sci. 22, 77-78.
33. Reiber H. and Peter J. B. (2001) Cerebrospinal fluid analysis: disease related data patterns and evaluation programs. J. Neurol. Sci. 184, 101-122.
34. Riemenschneider M., Schmolke M., Lautenschlager N., Guder W. G., Vanderstichele H., Vanmechelen E., and Kurz A. (2000) Cerebrospinal beta-amyloid (1-42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. Neurosci. Lett. 284, 85-88.
35. Rosner H., Rebhan M., Vacun G., and Vanmechelen E. (1995) Developmental expression of tau proteins in the chicken and rat brain: rapid down-regulation of a paired helical filament epitope in the rat cerebral cortex coincides with the transition from immature to adult tau isoforms. Int. J. Dev. Neurosci. 13, 607-617.
36. Shahani N. and Brandt R. (2002) Functions and malfunctions of the tau proteins. Cell. Mol. Life Sci. 59, 1668-1680.
37. Stamer K., Vogel R., Thies E., Mandelkow E., and Mandelkow E. M. (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156, 1051-1063.
38. Takei Y., Teng J., Harada A., and Hirokawa N. (2000) Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J. Cell Biol. 150, 989-1000.
39. Trojanowski J. Q. and Lee V. M. (1995) Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. FASEB J. 9, 1570-1576.
40. Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van Der Perre B., Sjogren M., et al. (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 285, 49-52.
41. Vanmechelen E., Vanderstichele H., Hulstaert F., Andreasen N., Minthon L., Winblad B., et al. (2001a) Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders. Mech. Ageing Dev. 122, 2005-2011.
42. Vanmechelen E., Van Kerschaver E., Blennow K., De Deyn P. P., Gartner F. H., Parnetti L., et al. (2001b) CSF-Phospho-tau (181P) as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies, in Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics, Iqbal, K., Sisodia, S. S., and Winblad, B., eds., John Wiley and Sons Ltd., Chichester, UK, pp. 285-291.
43. Wiltfang J., Esselmann H., Bibl M., Smirnov A., Otto M., Paul S., et al. (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 81, 481-496.
44. Wiltfang J., Esselmann H., Cupers P., Neumann M., Kretzschmar H., Beyermann M., et al. (2001) Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J. Biol. Chem. 276, 42645-42657.